A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient(216 views visite) Di Lorenzo G, Imbimbo M, Leopardo D, Marciano R, Federico P, Buonerba C, Salvatore B, Marinelli A, Palmieri G. A
Int J Immunopathol Pharmacol (ISSN: 0394-6320), 2010 Jul; 23(3): 951-954.
Keywords Parole chiave: Advanced Disease, Hepatocellular Carcinoma, Sorafenib, Adult, Advanced Cancer, Article, Cancer Survival, Case Report, Chemoembolization, Drug Dose Reduction, Drug Efficacy, Drug Withdrawal, Febrile Neutropenia, Follow Up, Hand Foot Syndrome, Heart Infarction, Human, Human Tissue, Liver Biopsy, Liver Cell Carcinoma, Multiple Cycle Treatment, Priority Journal, Progression Free Survival, Treatment Response, Treatment Withdrawal, Antineoplastic Agents, Benzenesulfonates, Disease Progression, Liver Neoplasms, Middle Aged, Myocardial Infarction, Pyridines, Tumor Markers, Biological,
Affiliations Affiliazioni: *** IBB - CNR ***
Department of Endocrinology and Clinical Oncology, Referential Rare Tumors Center, University Federico II, Naples, Italy Radiology Division, University Federico II, Naples, Italy
References Riferimenti: Shariff, M.I., Cox, I.J., Gomaa, A.I., Khan, S.A., Gedroyc, W., Taylor-Robinson, S.D., Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics (2009) Expert Rev Gastroenterol Hepatol, 3, pp. 353-36
Llovet, J.M., Ricci, S., Mazzaferro, V., Sorafenib in advanced hepatocellular carcinoma (2008) N Engl J Med, 359, pp. 378-390
Cheng, A.L., Kang, Y.K., Chen, Z., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial (2009) Lancet Oncol, 10, pp. 25-34
Orphanos, G.S., Ioannidis, G.N., Ardavanis, A.G., Cardiotoxicity induced by tyrosine kinase inhibitors (2009) Acta Oncol, pp. 48964-48970
Di Lorenzo, G., Autorino, R., Bruni, G., Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis (2009) Ann Oncol, 20, pp. 1535-1542
Shariff, M. I., Cox, I. J., Gomaa, A. I., Khan, S. A., Gedroyc, W., Taylor-Robinson, S. D., Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics (2009) Expert Rev Gastroenterol Hepatol, 3, pp. 353-36
Llovet, J. M., Ricci, S., Mazzaferro, V., Sorafenib in advanced hepatocellular carcinoma (2008) N Engl J Med, 359, pp. 378-390
Cheng, A. L., Kang, Y. K., Chen, Z., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial (2009) Lancet Oncol, 10, pp. 25-34
Orphanos, G. S., Ioannidis, G. N., Ardavanis, A. G., Cardiotoxicity induced by tyrosine kinase inhibitors (2009) Acta Oncol, pp. 48964-48970
A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(206 visite) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 DettagliEsporta in BibTeXEsporta in EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G * CaMK4 gene deletion induces hypertension(284 visite) J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D. Impact Factor:2.882 DettagliEsporta in BibTeXEsporta in EndNote
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(422 visite) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 DettagliEsporta in BibTeXEsporta in EndNote
Malvindi MA, Greco A, Conversano F, Figuerola A, Corti M, Bonora M, Lascialfari A, Doumari HA, Moscardini M, Cingolani R, Gigli G, Casciaro S, Pellegrino T, Ragusa A * MR Contrast Agents(230 visite) Small Animal Imaging, 2011 Jul 8; 21(13): 2548-2555. Impact Factor:1.784 DettagliEsporta in BibTeXEsporta in EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(409 visite) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 DettagliEsporta in BibTeXEsporta in EndNote